Curbside Consults Podcast

Published June 13, 2019

Infective endocarditis is a rare infection associated with a high mortality. Patients are often admitted for prolonged periods of time to receive antibiotics. The Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis or the POET trial asked the question whether patients with left sided infective endocarditis can be switched to oral treatment after stabilization on intravenous antibiotics. In this episode, our expert Dr Henry Chambers discusses infective endocarditis and the recently published POET trial.

00:00 Introduction
01:23 Microbiology of infective endocarditis (IE)
04:11 Clinical signs and symptoms of IE
06:10 Diagnosis of IE
08:56 Imaging for IE
11:37 General treatment principles for IE
14:11 Surgical Indications for IE
15:20 Why is the POET trial important?
16:59 Trial design and patient characteristics
22:07 Antibiotic regimen in the trial
23:54 Primary outcome in the trial
25:38 Summary of the podcast
27:00 Conclusion

Additional Resources:

1. Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis
2. Infective Endocarditis

The Curbside Consults series complements the foundational information in NEJM R360 Rotation Prep by taking a deep dive into key clinical topics with expert clinicians and educators. These podcasts explore and critique the evidence behind clinical practice and break down statistical concepts for the busy clinical trainee.

Dr. Henry "Chip" Chambers clinical and research interests are antimicrobial drug resistance, staphylococcal infections, experimental therapeutics, and epidemiology and pathogenesis of disease caused by Staphylococcus aureus. He is editor for the Sanford Guide to Antimicrobial Therapy and he has over 200 original publications and textbook chapters in the areas of drug resistance, endocarditis, bacterial infections, and staphylococcal diseases. Dr. Chambers received his BA from Centre College in Kentucky and is a graduate of the Vanderbilt University School of Medicine. He trained in Internal Medicine and Infectious Diseases at the University of California San Francisco. Dr. Chambers has been a member of the medical faculty of the UCSF since 1983 where he currently is Professor of Medicine, Medical Director of Clinical Research Services for CTSI. He is an editor for Antimicrobial Agents and Chemotherapy, a reviewer for numerous medical publications, a peer reviewer for NIH study sections.
Amanda Fernandes is a 2018-2019 NEJM editorial fellow.